Creative Bioarray Develops State-of-art Cell Based Assay to Support Biomedical Research and Drug-discovery Process
Cell assay platform, the branch of Creative Bioarray, is major in developing high-quality products and services to accelerate the research in apoptosis, cell necrosis, autophagy, ferroptosis, pyroptosis and other fields. Creative Bioarray is committed to providing a full range of research consulting to help researchers gain the most suitable research solutions. Recently, Creative Bioarray develops a state-of-art cell-based assay to support biomedical research and drug discovery processes.
Phenotypic screening of compounds in a multi-cell humanized environment provides richer data and can be quickly translated into clinical applications. Human primary cell-based tests, such as cell proliferation testing, cell viability testing, and GPCR testing, are developed using cells from tissues, blood, or differentiated stem cells, and can be used for high-content analysis of indications in more than 20 different disease regions. These high-throughput tests accelerate drug discovery by providing the correct candidates in the most relevant biology.
In a simple cell test with little physiological relevance, limited target-based screening has been developed into multicellular cell-based functional and biochemical tests for drug discovery in disease-related platforms. In order to better understand the complex interactions of networks and pathways in these cellular processes, Creative Bioarray has developed cell-based detection methods for each stage of drug development. By using mature and innovative technologies to obtain a range of cell types, analysis can be developed to best simulate your disease state, thereby increasing the conversion success rate.
Creative Bioarray simulates the cell environment through a variety of cell types: human primary cells-how to develop compounds that can be provided by using disease-related cells in vitro to be transformed into the earliest predictive assay in the clinic, which is suitable for therapeutic fields such as oncology, neuroscience and immunology. When human cells related to the disease are not available, induced pluripotent cells (iPSC) can be used to generate a large number of cells with different tissue types. Creative Bioarray has extensive experience in stem cell culture and differentiation and can provide reliable test quality for cell-based tests.
Creative Bioarray provides customized assay development and screening with readouts, including high-content analysis and multi-parameter testing. From early detection to transformation to in vivo pharmacology, the right combination of cell-based testing can provide predictive data in the process of the drug development pathway.
“Our mission is to provide customers with a professional cell biology research platform. With high-quality products, professional services and effective research solutions, we are committed to helping customers achieve effective and successful research goals.” said Hannah Cole, the marketing director of Creative Bioarray, she also claimed, “We provide one-stop service from order placement to final report, and provide the best solution for your research.”
Phenotypic screening of compounds in a multi-cell humanized environment provides richer data and can be quickly translated into clinical applications. Human primary cell-based tests, such as cell proliferation testing, cell viability testing, and GPCR testing, are developed using cells from tissues, blood, or differentiated stem cells, and can be used for high-content analysis of indications in more than 20 different disease regions. These high-throughput tests accelerate drug discovery by providing the correct candidates in the most relevant biology.
In a simple cell test with little physiological relevance, limited target-based screening has been developed into multicellular cell-based functional and biochemical tests for drug discovery in disease-related platforms. In order to better understand the complex interactions of networks and pathways in these cellular processes, Creative Bioarray has developed cell-based detection methods for each stage of drug development. By using mature and innovative technologies to obtain a range of cell types, analysis can be developed to best simulate your disease state, thereby increasing the conversion success rate.
Creative Bioarray simulates the cell environment through a variety of cell types: human primary cells-how to develop compounds that can be provided by using disease-related cells in vitro to be transformed into the earliest predictive assay in the clinic, which is suitable for therapeutic fields such as oncology, neuroscience and immunology. When human cells related to the disease are not available, induced pluripotent cells (iPSC) can be used to generate a large number of cells with different tissue types. Creative Bioarray has extensive experience in stem cell culture and differentiation and can provide reliable test quality for cell-based tests.
Creative Bioarray provides customized assay development and screening with readouts, including high-content analysis and multi-parameter testing. From early detection to transformation to in vivo pharmacology, the right combination of cell-based testing can provide predictive data in the process of the drug development pathway.
“Our mission is to provide customers with a professional cell biology research platform. With high-quality products, professional services and effective research solutions, we are committed to helping customers achieve effective and successful research goals.” said Hannah Cole, the marketing director of Creative Bioarray, she also claimed, “We provide one-stop service from order placement to final report, and provide the best solution for your research.”
